Potent antiviral activity of north-methanocarbathymidine against Kaposi's sarcoma-associated herpesvirus

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 12, 2005, Pages 4965-4973

  Zhu, Weimin ^a,c   Burnette, Angela ^a,d   Dorjsuren, Dorjbal ^a,c   Roberts, Paula E ^a,e   Huleihel, Mahmoud ^b   Shoemaker, Robert H ^c   Marquez, Victor E ^c   Agbaria, Riad ^b   Sei, Shizuko ^a,c  

^a SAIC FREDERICK INC   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SuperArray Bioscience Corporation   (United States)

^e SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' METHANOCARBATHYMIDINE; 2' METHANOCARBATHYMIDINE TRIPHOSPHATE; 5' ETHYNYLTHYMIDINE; ANTIVIRUS AGENT; CARBOCYCLIC THYMIDINE; CIDOFOVIR; CIDOFOVIR DIPHOSPHATE; DNA POLYMERASE; DRUG METABOLITE; GANCICLOVIR; GANCICLOVIR TRIPHOSPHATE; THYMIDINE DERIVATIVE; THYMIDINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CARCINOGENESIS; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DNA SYNTHESIS INHIBITION; DRUG CONFORMATION; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; IC 50; KAPOSI SARCOMA; METABOLITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRION; VIRUS INFECTION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HERPESVIRUS 8, HUMAN; HUMANS; INHIBITORY CONCENTRATION 50; SARCOMA, KAPOSI; THYMIDINE; TUMOR CELLS, CULTURED;

EID: 28844434895     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.12.4965-4973.2005     Document Type: Article

References (64)

1. Anonymous. 1981. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men-New York City and California. Morb. Mortal. Wkly. Rep. 30:305-308.
2. Atkinson, M. R., M. P. Deutscher, A. Kornberg, A. F. Russell, and J. G. Moffatt. 1969. Enzymatic synthesis of deoxyribonucleic acid. XXXIV. Termination of chain growth by a 2′,3′-dideoxyribonucleotide. Biochemistry 8:4897-4904.
3. Balzarini, J., E. De Clercq, A. Verbruggen, D. Ayusawa, K. Shimizu, and T. Seno. 1987. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene. Mol. Pharmacol. 32:410-416.
4. Boyer, P. L., J. G. Julias, V. E. Marquez, and S. H. Hughes. 2005. Fixed conformation nucleoside analogs effectively inhibit excision-proficient HIV-1 reverse transcriptases. J. Mol. Biol. 345:441-450.
5. Brutlag, D., and A. Kornberg. 1972. Enzymatic synthesis of deoxyribonucleic acid. 36. A proofreading function for the 3′ leads to 5′ exonuclcase activity in deoxyribonucleic acid polymerases. J. Biol. Chem. 247:241-248.
6. Campbell, T. B., M. Borok, L. Gwanzura, S. MaWhinney, I. E. White, B. Ndemera, I. Gudza, L. Fitzpatrick, and R. T. Schooley. 2000. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 14:2109-2116.
7. Cannon, J. S., F. Hamzeh, S. Moore, J. Nicholas, and R. F. Ambinder. 1999. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J. Virol. 73:4786-4793.
8. Cesarman, E., Y. Chang, P. S. Moore, J. W. Said, and D. M. Knowles. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332:1186-1191.
9. Chang, Y., E. Cesarman, M. S. Pessin, F. Lee, J. Culpepper, D. M. Knowles, and P. S. Moore. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869.
10. Chen, M. S., J. Walker, and W. H. Prusoff. 1979. Kinetic studies of herpes simplex virus type 1-encoded thymidine and thymidylate kinase, a multifunctional enzyme. J. Biol. Chem. 254:10747-10753.
11. Cihlar, T., and M. S. Chen. 1996. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 50:1502-1510.
12. Dorjsuren, D., Y. Badralmaa, J. Mikovits, A. Li, R. Fisher, R. Ricciardi, R. Shoemaker, and S. Sei. 2003. Expression and purification of recombinant Kaposi's sarcoma-associated herpesvirus DNA polymerase using a Baculovirus vector system. Protein Expr. Purif. 29:42-50.
13. Dupont, C., E. Vasseur, A. Beauchet, P. Aegerter, H. Berthe, P. de Truchis, D. Zucman, E. Rouveix, and P. Saiag. 2000. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodeficience humaine. AIDS 14:987-993.
14. Ensoli, B., C. Sgadari, G. Barillari, M. C. Sirianni, M. Sturzl, and P. Monini. 2001. Biology of Kaposi's sarcoma. Eur. J. Cancer 37:1251-1269.
15. Farge, D. 1993. Kaposi's sarcoma in organ transplant recipients. The Collaborative Transplantation Research Group of Ile de France. Eur. J. Med. 2:339-343.
16. Farge, D., C. Lebbe, Z. Marjanovic, P. Tuppin, C. Mouquet, M. N. Peraldi, P. Lang, C. Hiesse, C. Antoine, C. Legendre, J. Bedrossian, M. F. Gagnadoux, C. Loirat, C. Pellet, J. Sheldon, J. L. Golmard, F. Agbalika, and T. F. Schulz. 1999. Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d' Ile de France (GCIF). Transplantation 67:1236-1242.
17. Field, A. K., M. E. Davies, C. DeWitt, H. C. Perry, R. Liou, J. Germershausen, J. D. Karkas, W. T. Ashton, D. B. Johnston, and R. L. Tolman. 1983. 9-([2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc. Natl. Acad. Sci. USA 80:4139-4143.
18. Friedman-Kien, A. E., and B. R. Saltzman. 1990. Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi's sarcoma. J. Am. Acad. Dermatol. 22:1237-1250.
19. Fyfe, J. A., P. M. Keller, P. A. Furman, R. L. Miller, and G. B. Elion. 1978. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J. Biol. Chem. 253:8721-8727.
20. Caspar, G., E. De Clercq, and J. Neyts. 2002. Human herpesvirus 8 gene encodes a functional thymidylate synthase. J. Virol. 76:10530-10532.
21. Gill, J., D. Bourboulia, J. Wilkinson, P. Hayes, A. Cope, A. G. Marcelin, V. Calvez, F. Gotch, C. Boshoff, and B. Gazzard. 2002. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J. Acquir. Immune Defic. Syndr. 31:384-390.
22. Gill, P. S., M. Rarick, J. A. McCutchan, L. Slater, B. Parker, E. Muchmore, M. Bernstein-Singer, B. Akil, B. M. Espina, M. Krailo, et al. 1991. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am. J. Med. 90:427-433.
23. Glesby, M. J., D. R. Hoover, S. Weng, N. M. Graham, J. P. Phair, R. Detels, M. Ho, and A. J. Saah. 1996. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect. Dis. 173:1477-1480.
24. Goscin, L. P., and J. J. Byrnes. 1982. DNA polymerase delta: one polypeptide, two activities. Biochemistry 21:2513-2518.
25. Gustafson, E. A., A. C. Chillemi, D. R. Sage, and J. D. Fingeroth. 1998. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob Agents Chemother. 42:2923-2931.
26. Gustafson, E. A., R. F. Schinazi, and J. D. Fingeroth. 2000. Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J. Virol. 74:684-692.
27. Hirt, B. 1967. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26:365-369.
28. Ho, H. T., K. L. Woods, J. J. Bronson, H. De Boeck, J. C. Martin, and M. J. Hitchcock. 1992. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol. Pharmacol. 41:197-202.
29. Hymes, K. B., T. Cheung, J. B. Greene, N. S. Prose, A. Marcus, H. Ballard, D. C. William, and L. J. Laubenstein. 1981. Kaposi's sarcoma in homosexual men-a report of eight cases. Lancet ii:598-600.
30. Kedes, D. H., and D. Ganem. 1997. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J. Clin. Investig. 99:2082-2086.
31. Kira, T., S. P. Grill, G. E. Dutschman, J. S. Lin, F. Qu, Y. Choi, C. K. Chu, and Y. C. Cheng. 2000. Anti-Epstein-Barr virus (EBV) activity of β-L-5-iododioxolane uracil is dependent on EBV thymidine kinase. Antimicrob. Agents Chemother. 44:3278-3284.
32. Knopf, K. W., E. R. Kaufman, and C. Crumpacker. 1981. Physical mapping of drug resistance mutations defines an active center of the herpes simplex virus DNA polymerase enzyme. J. Virol. 39:746-757.
33. Krown, S. E. 2003. Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms. Hematol. Oncol. Clin. N. Am. 17:763-783.
34. Lemlich, G., L. Schwam, and M. Lebwohl. 1987. Kaposi's sarcoma and acquired immunodeficiency syndrome. Postmortem findings in twenty-four cases. J. Am. Acad. Dermatol. 16:319-325.
35. Marcy, A. I., P. D. Olivo, M. D. Challberg, and D. M. Coen. 1990. Enzymatic activities of overexpressed herpes simplex virus DNA polymerase purified from recombinant baculovirus-infected insect cells. Nucleic Acids Res. 18:1207-1215.
36. Marquez, V. E., T. Ben-Kasus, J. J. Barchi, Jr., K. M. Green, M. C. Nicklaus, and R. Agbaria. 2004. Experimental and structural evidence that herpes 1 kinase and cellular DNA polymerase(s) discriminate on the basis of sugar pucker. J. Am. Chem. Soc. 126:543-549.
37. Marquez, V. E., M. A. Siddiqui, A. Ezzitouni, P. Russ, J. Wang, R. W. Wagner, and M. D. Matteucci. 1996. Nucleosides with a twist. Can fixed forms of sugar ring pucker influence biological activity in nucleosides and oligonucleotides? J. Med. Chem. 39:3739-3747.
38. Martin, D. F., B. D. Kuppermann, R. A. Wolitz, A. G. Palestine, H. Li, and C. A. Robinson. 1999. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N. Engl. J. Med. 340:1063-1070.
39. Medveczky, M. M., E. Horvath, T. Lund, and P. G. Medveczky. 1997. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 11:1327-1332.
40. Mocroft, A., M. Youle, B. Gazzard, J. Morcinek, R. Halai, and A. N. Phillips. 1996. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 10:1101-1105.
41. Moore, P. S., and Y. Chang. 1995. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N. Engl. J. Med. 332:1181-1185.
42. Moore, P. S., S. J. Gao, G. Dominguez, E. Cesarman, O. Lungu, D. M. Knowles, R. Garber, P. E. Pellett, D. J. McGeoch, and Y. Chang. 1996. Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma. J. Virol. 70:549-558.
43. Nutter, L. M., S. P. Grill, G. E. Dutschman, R. A. Sharma, M. Bobek, and Y. C. Cheng. 1987. Demonstration of viral thymidine kinase inhibitor and its effect on deoxynucleotide metabolism in cells infected with herpes simplex virus. Antimicrob. Agents Chemother. 31:368-374.
44. Pellet, C., S. Chevret, C. Frances, S. Euvrard, M. Hurault, C. Legendre, S. Dalac, D. Farge, C. Antoine, C. Hiesse, M. N. Peraldi, P. Lang, D. Samuel, Y. Calmus, F. Agbalika, P. Morel, F. Calvo, and C. Lebbe. 2002. Prognostic value of quantitative Kaposi sarcoma-associated herpesvirus load in posttransplantation Kaposi sarcoma. J. Infect. Dis. 186:110-113.
45. Quinlivan, E. B., C. Zhang, P. W. Stewart, C. Komoltri, M. G. Davis, and R. S. Wehbie. 2002. Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not. J. Infect. Dis. 185:1736-1744.
46. Qunibi, W., M. Akhtar, K. Sheth, H. E. Ginn, O. Al-Furayh, E. B. DeVol, and S. Taher. 1988. Kaposi's sarcoma: the most common tumor after renal transplantation in Saudi Arabia. Am. J. Med. 84:225-232.
47. Reid, R., E. C. Mar, E. S. Huang, and M. D. Topal. 1988. Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human alpha and human beta polymerases. A unique inhibition mechanism for 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate. J. Biol. Chem. 263:3898-3904.
48. Renne, R., W. Zhong, B. Herndier, M. McGrath, N. Abbey, D. Kedes, and D. Ganem. 1996. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat. Med. 2:342-346.
49. Renwick, N., T. Halaby, G. J. Weverling, N. H. Dukers, G. R. Simpson, R. A. Coutinho, J. M. Lange, T. F. Schulz, and J. Goudsmit. 1998. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS 12:2481-2488.
50. Ricciardi, R. P., K. Lin, X. Chen, D. Dorjsuren, R. Shoemaker, and S. Sei. 2004. Rapid screening of chemical inhibitors that block processive DNA synthesis of herpesviruses: potential application to high-throughput screening. Methods Mol. Biol. 292:481-492.
51. Russo, J. J., R. A. Bohenzky, M. C. Chien, J. Chen, M. Yan, D. Maddalena, J. P. Parry, D. Peruzzi, I. S. Edelman, Y. Chang, and P. S. Moore. 1996. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl. Acad. Sci. USA 93:14862-14867.
52. Schelling, P., M. T. Claus, R. Johner, V. E. Marquez, G. E. Schulz, and L. Scapozza. 2004. Biochemical and structural characterization of (South)-methanocarhathymidine that specifically inhibits growth of herpes simplex virus type 1 thymidine kinase-transduced osteosarcoma cells. J. Biol. Chem. 279:32832-32838.
53. Sei, S., Q. E. Yang, D. O'Neill, K. Yoshimura, K. Nagashima, and H. Mitsuya. 2000. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J. Virol. 74:4621-4633.
54. Shepherd, F. A., E. Maher, C. Cardella, E. Cole, P. Greig, J. A. Wade, and G. Levy. 1997. Treatment of Kaposi's sarcoma after solid organ transplantation. J. Clin. Oncol. 15:2371-2377.
55. Song, L., M. Chaudhuri, C. W. Knopf, and D. S. Parris. 2004. Contribution of the 3′- to 5′-exonuclease activity of herpes simplex virus type 1 DNA polymerase to the fidelity of DNA synthesis. J. Biol. Chem. 279:18535-18543.
56. Soulier, J., L. Grollet, E. Oksenhendler, P. Cacoub, D. Cazals-Hatem, P. Babinet, M. F. d'Agay, J. P. Clauvel, M. Raphael, L. Degos, et al. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86:1276-1280.
57. Tsurumi, T., T. Daikoku, and Y. Nishiyama. 1994. Further characterization of the interaction between the Epstein-Barr virus DNA polymerase catalytic subunit and its accessory subunit with regard to the 3′-to-5′ exonucleolytic activity and stability of initiation complex at primer terminus. J. Virol. 68:3354-3363.
58. Weislow, O. S., R. Kiser, D. L. Fine, J. Bader, R. H. Shoemaker, and M. R. Boyd. 1989. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81:577-586.
59. Welles, L., M. W. Saville, J. Lietzau, J. M. Pluda, K. M. Wyvill, I. Feuerstein, W. D. Figg, R. Lush, J. Odom, W. H. Wilson, M. T. Fajardo, R. W. Humphrey, E. Feigal, D. Tuck, S. M. Steinberg, S. Broder, and R. Yarchoan. 1998. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J. Clin. Oncol. 16:1112-1121.
60. Whitby, D., M. R. Howard, M. Tenant-Flowers, N. S. Brink, A. Copas, C. Boshoff, T. Hatzioannou, F. E. Suggett, D. M. Aldam, A. S. Denton, et al. 1995. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 346:799-802.
61. Wu, F. Y., J. H. Ahn, D. J. Alcendor, W. J. Jang, J. Xiao, S. D. Hayward, and G. S. Hayward. 2001. Origin-independent assembly of Kaposi's sarcoma-associated herpesvirus DNA replication compartments in transient cotransfection assays and association with the ORF-K8 protein and cellular PML. J. Virol. 75:1487-1506.
62. Xiong, X., J. L. Smith, and M. S. Chen. 1997. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 41:594-599.
63. Yang, Q. E., A. G. Stephen, J. W. Adelsberger, P. E. Roberts, W. Zhu, M. J. Currens, Y. Feng, B. J. Crise, R. J. Gorelick, A. R. Rein, R. J. Fisher, R. H. Shoemaker, and S. Sei. 2005. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4. J. Virol. 79:6122-6133.
64. Zalah, L., M. Huleihel, E. Manor, A. Konson, H. Ford, Jr., V. E. Marquez, D. G. Johns, and R. Agbaria. 2002. Metabolic pathways of N- methanocarbathymidine, a novel antiviral agent, in native and herpes simplex virus type 1 infected Vero cells. Antiviral Res. 55:63-75.